Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
ByAinvest
Monday, Aug 25, 2025 4:38 am ET1min read
EW--
Prior to joining Pulnovo, Dr. Duhay served as the Chief Medical Officer at Edwards Lifesciences (NYSE: EW), where he played a crucial role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR). The TAVR program, now recognized as one of the most successful cardiovascular procedures in history, generates over $4.0 billion in annual revenue and has been adopted in more than 80 countries [1].
Dr. Duhay's extensive experience includes leading 88 clinical studies across multiple specialties and collaborating with global regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) [2]. His appointment at Pulnovo strengthens the company's global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands its footprint in international markets.
With Dr. Duhay's proven track record in bringing paradigm-shifting cardiovascular technologies from concept to global standard of care, Pulnovo is well-positioned for its next phase of innovation and growth.
References:
[1] https://www.prnewswire.com/news-releases/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-officer-302537529.html
[2] https://www.stocktitan.net/news/EW/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-jzn2kovl39s3.html
Pulnovo Medical has appointed Francis Duhay, MD, MBA, FACS, as its Global Chief Medical Officer. Duhay brings 25 years of experience in clinical medicine, medical device innovation, and executive leadership, including a role as Chief Medical Officer at Edwards Lifesciences. He will lead Pulnovo's Pulmonary Artery Denervation program and expand its international presence.
Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), has appointed Dr. Francis Duhay, MD, MBA, FACS, as its Global Chief Medical Officer. Dr. Duhay brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership to the role.Prior to joining Pulnovo, Dr. Duhay served as the Chief Medical Officer at Edwards Lifesciences (NYSE: EW), where he played a crucial role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR). The TAVR program, now recognized as one of the most successful cardiovascular procedures in history, generates over $4.0 billion in annual revenue and has been adopted in more than 80 countries [1].
Dr. Duhay's extensive experience includes leading 88 clinical studies across multiple specialties and collaborating with global regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) [2]. His appointment at Pulnovo strengthens the company's global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands its footprint in international markets.
With Dr. Duhay's proven track record in bringing paradigm-shifting cardiovascular technologies from concept to global standard of care, Pulnovo is well-positioned for its next phase of innovation and growth.
References:
[1] https://www.prnewswire.com/news-releases/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-officer-302537529.html
[2] https://www.stocktitan.net/news/EW/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-jzn2kovl39s3.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet